Idera's Hep C Drug Put on Hold
Idera delays hepatitis-C drug trials
Friday, April 22, 2011
By Rodney H. Brown
Idera Pharmaceuticals Inc. has put the brakes on a Phase 2 trial of a treatment for a specific type of hepatitis C because early data showed certain types of cancerous growth in lab rats.
The trial was evaluating IMO-2125 plus ribavirin in treatment-naïve, genotype 1 hepatitis C virus (HCV) patients. Once Cambridge pharmaceutical Idera (Nasdaq: IDRA) evaluated toxicology studies involving rodents and non-human primates, researchers noticed that the rats showed instances of a condition called atypical lymphocytic proliferation.
Continue reading this entire article: